New drug tested for debilitating nerve disease

NCT ID NCT04658472

Summary

This study tested an experimental drug called SAR445088 in adults with CIDP, a rare condition that causes progressive weakness and numbness. The main goal was to see if the drug could control the disease and prevent relapses in different groups of patients, including those who do not respond well to standard treatments. Researchers also monitored the drug's safety and how well it was tolerated over a long period.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Columbia University Site Number : 8400005

    New York, New York, 10032, United States

  • Investigational Site Number : 1240001

    Gatineau, Quebec, J8Y 1W2, Canada

  • Investigational Site Number : 1240002

    Québec, G1J 1Z4, Canada

  • Investigational Site Number : 1560001

    Shanghai, 200040, China

  • Investigational Site Number : 1560002

    Fuzhou, 350001, China

  • Investigational Site Number : 1560004

    Wuhan, 430030, China

  • Investigational Site Number : 2500001

    Marseille, 13385, France

  • Investigational Site Number : 2500002

    Nice, 06002, France

  • Investigational Site Number : 2500003

    Bordeaux, France

  • Investigational Site Number : 2500004

    Garches, 92380, France

  • Investigational Site Number : 2500005

    Le Kremlin-Bicêtre, 94275, France

  • Investigational Site Number : 2760001

    Düsseldorf, 40225, Germany

  • Investigational Site Number : 2760002

    Göttingen, 37075, Germany

  • Investigational Site Number : 2760003

    Essen, 45147, Germany

  • Investigational Site Number : 2760004

    Tübingen, 72076, Germany

  • Investigational Site Number : 3800001

    Milan, 20132, Italy

  • Investigational Site Number : 3800002

    Rome, Lazio, 00168, Italy

  • Investigational Site Number : 3800003

    Genova, 16132, Italy

  • Investigational Site Number : 3800005

    Rozzano, Milano, 20089, Italy

  • Investigational Site Number : 5280001

    Amsterdam, 1105AZ, Netherlands

  • Investigational Site Number : 5280002

    Utrecht, 3584 CX, Netherlands

  • Investigational Site Number : 6160001

    Lublin, Lublin Voivodeship, 20-954, Poland

  • Investigational Site Number : 6880001

    Belgrade, 11000, Serbia

  • Investigational Site Number : 6880002

    Belgrade, 11000, Serbia

  • Investigational Site Number : 6880003

    Niš, 18000, Serbia

  • Investigational Site Number : 7240001

    Barcelona, Barcelona [Barcelona], 08041, Spain

  • Investigational Site Number : 7240002

    Barcelona, Barcelona [Barcelona], 08035, Spain

  • Investigational Site Number : 7240003

    Valencia, 46026, Spain

  • The University of Kansas Clinical Research Center Site Number : 8400003

    Fairway, Kansas, 66205, United States

  • University of California Irvine Site Number : 8400002

    Orange, California, 92868, United States

  • University of Minnesota Site Number : 8400006

    Minneapolis, Minnesota, 55414, United States

  • University of Southern California Site Number : 8400004

    Los Angeles, California, 90033, United States

Conditions

Explore the condition pages connected to this study.